Hennessy Advisors Inc. Has $4.48 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Hennessy Advisors Inc. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 61,100 shares of the biopharmaceutical company’s stock after purchasing an additional 400 shares during the quarter. Hennessy Advisors Inc.’s holdings in Gilead Sciences were worth $4,476,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Etesian Wealth Advisors Inc. raised its position in Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after acquiring an additional 128 shares in the last quarter. Financial Counselors Inc. lifted its stake in Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 128 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares during the period. Steph & Co. increased its position in Gilead Sciences by 1.9% during the fourth quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock worth $611,000 after buying an additional 142 shares during the last quarter. Finally, First Affirmative Financial Network lifted its position in shares of Gilead Sciences by 3.5% in the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 147 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Maxim Group reduced their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Royal Bank of Canada reissued a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research note on Friday, June 14th. Oppenheimer restated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. TD Cowen decreased their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Finally, HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a report on Wednesday, April 24th. Twelve analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average price target of $83.47.

Gilead Sciences Trading Down 0.7 %

Shares of Gilead Sciences stock traded down $0.48 on Thursday, reaching $68.83. 6,859,832 shares of the company’s stock were exchanged, compared to its average volume of 7,638,361. The company has a market capitalization of $85.75 billion, a P/E ratio of 191.19, a price-to-earnings-growth ratio of 2.96 and a beta of 0.20. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The firm’s 50-day moving average is $65.89 and its two-hundred day moving average is $72.75.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter in the prior year, the firm earned $1.37 EPS. The business’s revenue was up 5.3% on a year-over-year basis. Sell-side analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.47%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.